Vedanta Biosciences said it significantly reduced headcount to concentrate capital and manpower on its lead live‑biotherapeutic VE303, a bacterial consortium targeting recurrent Clostridioides difficile infection, and to progress a planned Phase 3 study intended to complete by mid‑2027. The company framed the move as a focused reallocation after prior program setbacks and a recent halt of another microbiome asset. Reports indicate major layoffs and furloughs, and Vedanta confirmed workforce reductions while declining to disclose full headcount numbers. Management emphasized phase 2 data supporting VE303 and cited the need to preserve runway to reach pivotal milestones or attract partners. The restructuring highlights funding and execution pressures in the microbiome field where manufacturing complexity, regulatory pathways and payor acceptance remain unresolved; success of VE303 will be pivotal for Vedanta’s survival or for attracting strategic suitors.